Related Experiment Video

Updated: May 8, 2026

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

Using network biology to bridge pharmacokinetics and pharmacodynamics in oncology

D C Kirouac1, M D Onsum

  • 1Merrimack Pharmaceuticals Inc., Cambridge, Massachusetts, USA.

CPT: Pharmacometrics & Systems Pharmacology
|September 6, 2013
PubMed

Insights

Integrating mechanistic signaling networks and drug pharmacokinetics (PK) into mathematical models is crucial for effective cancer drug development. This approach enables in silico design of combination therapies and identification of predictive biomarkers.

Area of Science:

  • Oncology
  • Pharmacometrics
  • Systems Biology

Background:

  • Effective cancer drug development requires models that integrate cellular signaling and drug pharmacokinetics (PK).
  • Current models often lack the multiscale detail needed to capture complex oncogenic signaling networks.

Purpose of the Study:

  • To present an approach for building multiscale mathematical models for cancer drug development.
  • To demonstrate the utility of these models for designing combination therapies and identifying predictive biomarkers in silico.

Main Methods:

  • Developing multiscale models that incorporate mechanistic details of cellular signal transduction networks.
  • Integrating pharmacokinetic (PK) properties of anticancer drugs into the models.
  • Utilizing systems-level architectural features of oncogenic signaling pathways.

Main Results:

  • The proposed approach allows for the creation of comprehensive mathematical models for cancer drug development.
  • These models can simulate the effects of drug interventions on signaling networks.
  • The models facilitate in silico identification of optimal combination therapies and predictive biomarkers.

Conclusions:

  • Multiscale mathematical modeling, integrating signaling and PK, is essential for advancing cancer drug development.
  • This approach offers a powerful platform for in silico drug design and biomarker discovery.
  • Future cancer therapeutics can benefit from models that capture systems-level complexity.

Related Concept Videos

Nonlinear Pharmacokinetics: Overview01:19

Nonlinear Pharmacokinetics: Overview

Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Nonlinear Pharmacokinetics: Role of Transporters01:27

Nonlinear Pharmacokinetics: Role of Transporters

A drug's nonlinear kinetics can be influenced by a diverse range of transporter proteins that serve as crucial players in drug distribution. These transporters, found within cells, can enhance or reduce local drug concentrations by facilitating the influx or efflux of drugs. For instance, the expression of xenobiotic transporters can be influenced by factors such as age and gender, potentially impacting the linearity of drug response.
Polymorphisms occurring in drug transporters can alter...
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding01:22

Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding

When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacokinetic–Pharmacodynamic Relationship: Model Components01:14

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...